EcoDrugPlus

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSAMXG00000025831
Gene Symbol: LOC103028088
2 Cross references
340 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSAMXG00000024912
Gene Symbol: LOC103042007
3 Cross references
319 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSAMXG00000041389
Gene Symbol: FRK
3 Cross references
216 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSAMXG00000034064
Gene Symbol: FRK
1 Cross references
216 Possible Orthologues:

Galectin-3-Like

Ensembl ID : ENSAMXG00000041645
Gene Symbol: LOC103035732
3 Cross references
220 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSAMXG00000003507
Gene Symbol: GABBR2
1 Cross references
208 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-1

Ensembl ID : ENSAMXG00000005864
Gene Symbol: LOC103026962
3 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha2

Ensembl ID : ENSAMXG00000039580
Gene Symbol: GABRA2
4 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSAMXG00000020340
Gene Symbol: GABRA3
3 Cross references
198 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha4

Ensembl ID : ENSAMXG00000005855
Gene Symbol: GABRA4
3 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSAMXG00000012810
Gene Symbol: GABRA5
3 Cross references
207 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6

Ensembl ID : ENSAMXG00000018951
Gene Symbol: GABRA6
3 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).